Article

OBJECTIVE: To test the hypothesis that macrophage migration inhibitory factor
(MIF) is elevated in the circulation of individuals with acute spinal cord injury
(SCI) compared with uninjured individuals. DESIGN: Prospective, observational
pilot study. SETTING: Academic medical center. PARTICIPANTS: Adults with acute
traumatic SCI (n=18) and uninjured participants (n=18), comparable in age and sex
distribution. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: The primary
outcome measure was the plasma MIF levels. Potential correlations were examined
between MIF and clinical/demographic variables. The secondary outcome was to
determine if other immune mediators were elevated in participants with acute SCI
and if their levels correlated with the MIF. RESULTS: MIF was significantly
elevated in subjects with acute SCI compared with control subjects at 0 to 3
(P<.0029), 4 to 7 (P<.0001), and 8 to 11 (P<.0015) days postinjury (DPI). At 0 to
3 DPI, levels of cytokines interleukin-6 (P<.00017), interleukin-9 (P<.0047),
interleukin-16 (P<.007), interleukin-18 (P<.014), chemokines growth-related
oncogene alpha/chemokine (C-X-C motif) ligand 1 (P<.0127) and macrophage
inflammatory protein 1-beta/chemokine (C-C motif) ligand 4 (P<.0015), and growth
factors hepatocyte growth factor (HGF) (P<.0001) and stem cell growth factor-beta
(P<.0103) were also significantly elevated in subjects with acute SCI. With the
exception of interleukin-9, all of these factors remained significantly elevated
at 4 to 7 DPI; a subset (interleukin-16, HGF, stem cell growth factor-beta)
remained elevated throughout the study. Within individuals, MIF levels correlated
with HGF (P<.018) and interleukin-16 (P<.01). CONCLUSIONS: These data demonstrate
that MIF is significantly elevated in subjects with acute SCI, supporting further
investigation of MIF and other inflammatory mediators in acute SCI, where they
may contribute to primary and secondary functional outcomes.
CI - Copyright (c) 2015 American Congress of Rehabilitation Medicine. Published by
Elsevier Inc. All rights reserved.

Langue : ANGLAIS